Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, Jianjun, Shi, Lewis Zhichang, Zhao, Hao, Chen, Jianfeng, Xiong, Liangwen, He, Qiuming, Chen, Tenghui, Roszik, Jason +8 more·2016·Cell

DOI 10.1016/j.cell.2016.08.069

Cited by (1,000)

Items 101–200 of 1,000

Genetic and non-genetic clonal diversity in cancer evolution
James R. Black, Nicholas McGranahan · 2021 · Nature reviews. Cancer
Immune mechanisms of toxicity from checkpoint inhibitors
S. Jennifer Wang, Stephanie K. Dougan, Michael Lawrence Dougan · 2023 · Trends in cancer
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, Courtney Makris, Purushottam Lamichhane, Rahul R. Deshmukh · 2020 · Translational Oncology
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Chao Wang, Yanqi Ye, Quanyin Hu, Adriano Bellotti, Zhen Gu · 2017 · Advanced Materials
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
Lawrence Peter Andrews, Samuel C. Butler, Jian Cui, Anthony Richard Cillo, Carly Cardello, Chang Liu, Erin A. Brunazzi, Andrew Baessler, Bingxian Xie, Sheryl R. Kunning et al. · 2024 · Cell
Spatial CRISPR genomics identifies regulators of the tumor microenvironment
Maxime Dhainaut, Samuel A. Rose, Güray Aktürk, Aleksandra Wroblewska, Sebastian Rune Nielsen, Eun Sook Park, Mark Buckup, Vladimir Roudko, Luisanna Pia, Robert E. Sweeney et al. · 2022 · Cell
Targeting m 6 A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer
Yi Bao, Jianning Zhai, Huarong Chen, Chi Chun Wong, Cong Liang, Yanqiang Ding, Dan Huang, Hongyan Gou, Danyu Chen, Yasi Pan et al. · 2023 · Gut
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion
Frangieh, Chris J., Melms, Johannes C., Thakore, Pratiksha I., Geiger-Schuller, Kathryn R., Ho, Patricia, Luoma, Adrienne M., Cleary, Brian, Jerby-Arnon, Livnat, Malu, Shruti, Cuoco, Michael S. et al. · 2021 · Nature Genetics
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Arnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau Comas, Philippe J. Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen et al. · 2020 · European Respiratory Journal
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, Shengqing Stan, Zhang, Wubing, Wang, Xiaoqing, Jiang, Peng, Traugh, Nicole, Li, Ziyi, Meyer, Clifford, Stewig, Blair, Xie, Yingtian, Bu, Xia et al. · 2021 · Cancer Discovery
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben et al. · 2019 · Cell
Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer
Zhou, Liye, Mudianto, Tenny, Ma, Xiaojing, Riley, Rachel, Uppaluri, Ravindra · 2020 · Clinical Cancer Research
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, Connie P.M. Duong, Miles Cameron Andrews, Loïc Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère et al. · 2019 · Cell Research
IFN-γ: A cytokine at the right time, is in the right place
J. D. Burke, Howard A. Young · 2019 · Seminars in Immunology
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker, Fang Zhao, Natalia Pieper, Christina Heeke, Raffaela Maltaner, Nadine Stadtler, Birgit Real, Nicola Bielefeld, Sebastian Howe, Benjamin Weide et al. · 2017 · Nature Communications
Clinical cancer immunotherapy: Current progress and prospects
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen, Di Zhu · 2022 · Frontiers in Immunology
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair, Heather J. Bax, Silvia Mele, Silvia Crescioli, Giulia Pellizzari, Atousa Khiabany, Mano Nakamura, R. J. C. Harris, Elise French, Ricarda M. Hoffmann et al. · 2019 · Frontiers in Immunology
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Fidelle, Marine, Rauber, Conrad, Alves Costa Silva, Carolina, Tian, Ai-Ling, Lahmar, Imran, de La Varende, Anne-Laure Mallard, Zhao, Liwei, Thelemaque, Cassandra, Lebhar, Isabelle, Messaoudene, Meriem et al. · 2023 · Science
Protein acylation: mechanisms, biological functions and therapeutic targets
Shuang Shang, Jing Liu, Fang Hua · 2022 · Signal Transduction and Targeted Therapy
Cancer immunotherapy: broadening the scope of targetable tumours
Jitske van den Bulk, Els M.E. Verdegaal, Noel F.C.C. de Miranda · 2018 · Open Biology
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
Maura L. Gillison, Keiko Akagi, Weihong Xiao, Bo Jiang, Robert K. L. Pickard, Jingfeng Li, Benjamin J. Swanson, Amit D. Agrawal, Mark Zucker, Birgit Stache-Crain et al. · 2018 · Genome Research
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Dubrot, Juan, Du, Peter P., Lane-Reticker, Sarah Kate, Kessler, Emily A., Muscato, Audrey J., Mehta, Arnav, Freeman, Samuel S., Allen, Peter M., Olander, Kira E., Ockerman, Kyle M. et al. · 2022 · Nature Immunology
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Hsuan-An Chen, Yu-Jui Ho, Riccardo Mezzadra, José M. Adrover, Ryan M. Smolkin, Changyu Zhu, Katharina Woess, Nicholas Bernstein, Georgia Schmitt, Linda E. Fong et al. · 2022 · Cancer Discovery
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Fei Zhou, Meng Qiao, Caicun Zhou · 2020 · Cellular and Molecular Immunology
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, Xiangyu, Li, Tianhang, Jiang, Rui, Yang, Xin, Guo, Hongqian, Yang, Rong · 2023 · Molecular Cancer
Cytokines in cancer
Courtney T. Stump, Stephanie K. Dougan · 2024 · Cancer Cell
IFN‐γ‐mediated inhibition of lung cancer correlates with PD‐L1 expression and is regulated by PI3K‐AKT signaling
Yi Gao, Jianjian Yang, Yixin Cai, Shengling Fu, Ni Zhang, Xiangning Fu, Lequn Li · 2018 · International Journal of Cancer
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam Jacob Schoenfeld, Darwin Ye, George J. Fromm, Hira A. Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu et al. · 2024 · Cancer Cell
Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
Sarah Christina Sasson, Stephanie M. Slevin, Vincent Cheung, Isar Nassiri, Anna Claire Olsson-Brown, Eve Fryer, Ricardo C. Ferreira, Dominik Trzupek, Tarun Gupta, Lulia Al‐Hillawi et al. · 2021 · Gastroenterology
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Aleksandra Popović, Elizabeth M. Jaffee, Neeha Zaidi · 2018 · Journal of Clinical Investigation
Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians
Michael Allgäuer, Jan Budczies, Petros Christopoulos, Volker Endris, Amelie Lier, Eugen Rempel, Anna‐Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring et al. · 2018 · Translational Lung Cancer Research
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
Dongni Shi, Xianqiu Wu, Yunting Jian, Junye Wang, Chengmei Huang, Shuang Mo, Yue Li, Fengtian Li, Chao Zhang, Dongsheng Zhang et al. · 2022 · Nature Communications
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Mirjana Efremova, Francesca Finotello, Dietmar Rieder, Zlatko Trajanoski · 2017 · Frontiers in Immunology
Cancer immunotherapy: it’s time to better predict patients’ response
Charlotte Pilard, Marie Ancion, Philippe Delvenne, Guy Jérusalem, Pascale Hubert, Michael F. Herfs · 2021 · British Journal of Cancer
Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors
Vladimir Roudko, Cansu Cimen Bozkus, Theofano Orfanelli, Christopher B. McClain, Caitlin E. Carr, Timothy J. O’Donnell, Lauren Chakraborty, Robert M. Samstein, Kuan‐lin Huang, Stephanie V. Blank et al. · 2020 · Cell
A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
Donghai Xiong, Yian Wang, Ming You · 2020 · Nature Communications
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Richard P. Tobin, Kimberly Rae Jordan, William Allen Robinson, Dana M. Davis, Virginia F. Borges, Rene C. Gonzalez, Karl D. Lewis, Martin D. McCarter · 2018 · International Immunopharmacology
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang et al. · 2019 · Clinical Cancer Research
Applications of Immunogenomics to Cancer
X. Shirley Liu, Elaine R. Mardis · 2017 · Cell
Molecular and cellular paradigms of multidrug resistance in cancer
Foram U. Vaidya, Abu Sufiyan Chhipa, Vinita Mishra, Vishal Kumar Gupta, Shiv Govind Rawat, Ajay Kumar, Chandramani Pathak · 2020 · Cancer Reports
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target
Xiaoqing Wang, Collin J. Tokheim, Shengqing Stan Gu, Binbin Wang, Qin Tang, Yihao Li, Nicole C. Traugh, Zexian Zeng, Yi Zhang, Ziyi Li et al. · 2021 · Cell
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard William Seymour · 2021 · Journal for ImmunoTherapy of Cancer
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
Nathan O. Siemers, James L. Holloway, Chang Han, Scott D. Chasalow, Petra Ross‐Macdonald, Charles F. Voliva, Joseph D. Szustakowski · 2017 · PLoS ONE
The Peptide Vaccine of the Future
Nelde, Annika, Rammensee, Hans-Georg, Walz, Juliane S. · 2021 · Molecular & Cellular Proteomics
The Interferon-Gamma Paradox in Cancer
M. Raza Zaidi · 2018 · Journal of Interferon & Cytokine Research
An innate-like Vδ1 + γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Yin Wu, Fernanda Kyle‐Cezar, Richard Woolf, Cristina Naceur‐Lombardelli, Julie Owen, Dhruva Biswas, Anna Lorenc, Pierre Vantourout, Patrycja Gazińska, Anita E. Grigoriadis et al. · 2019 · Science Translational Medicine
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou, Noushin Niknafs, Kristen Ashley Marrone, Daniel C. Bruhm, James Robert White, Jarushka Naidoo, Karlijn Hummelink, Kim Monkhorst, Ferry Lalezari, Mara R. Lanis et al. · 2020 · Nature Cancer
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu · 2020 · Immunity
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elísabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento‐Ribeiro, Marilina García‐Aranda, Javier De Las Rivas · 2020 · Drug Resistance Updates
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, Rodion A. Velichinskii, Randy W. Lesh, Usman Ali, Michal Jakub Kubiak, Pranshu Bansal, Hossein Borghaei, Martin Joseph Edelman, Yanis Boumber · 2019 · Advances in Therapy
LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
Gaopeng Li, Ilona Kryczek, Jutaek Nam, Xiong Li, Shasha Li, Jing Li, Shuang Wei, Sara Grove, Linda Vatan, Jiajia Zhou et al. · 2021 · Nature Cell Biology
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Molecular Cancer
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung · 2018 · Experimental & Molecular Medicine
Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma
Limeta, Angelo, Ji, Boyang, Levin, Max, Gatto, Francesco, Nielsen, Jens · 2020 · JCI Insight
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi, Matthew David Hellmann, Monica B. Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama et al. · 2023 · Nature Genetics
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn, Sudha Rao · 2017 · Molecular Immunology
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, Parsa Modareszadeh, Eranda Berisha, Parinaz Sadat Alemi, Maria del Carmen Chacon Castro, Alexander R. Deese, Zhang Li · 2022 · Cancers
Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanoma
Falahat, Rana, Berglund, Anders, Putney, Ryan M., Perez-Villarroel, Patricio, Aoyama, Shota, Pilon-Thomas, Shari, Barber, Glen N., Mulé, James J. · 2021 · Proceedings of the National Academy of Sciences
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Md Aslam Hossain · 2024 · International Immunopharmacology
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, Kenji, Yaguchi, Tomonori, Tajima, Masaki, Honjo, Tasuku · 2023 · Nature Reviews Immunology
Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti · 2018 · Frontiers in Oncology
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Derya Kabacaoğlu, Katrin J. Ciecielski, Dietrich Alexander Ruess, Hana Algül · 2018 · Frontiers in Immunology
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
Xian-De Liu, Wen Kong, Christine B. Peterson, Daniel James McGrail, Anh G. Hoang, Xuesong Zhang, Truong Lam, Patrick Glen Pilie, Haifeng Zhu, Kathryn Eby Beckermann et al. · 2020 · Nature Communications
Inhibitors of the PD-1 Pathway in Tumor Therapy
Martin W. LaFleur, Yuki Muroyama, Charles G. Drake, Arlene H. Sharpe · 2018 · The Journal of Immunology
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
Sachet Ashok Shukla, Pavan Bachireddy, Bastian Schilling, Christina Galonska, Qian Zhan, Clyde Bango, Rupert Langer, Patrick C. Lee, Daniel Gusenleitner, Derin B. Keskin et al. · 2018 · Cell
Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens
Wroblewska, Aleksandra, Dhainaut, Maxime, Ben-Zvi, Benjamin, Rose, Samuel A., Park, Eun Sook, Amir, El-Ad David, Bektesevic, Anela, Baccarini, Alessia, Merad, Miriam, Rahman, Adeeb H. et al. · 2018 · Cell
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
Trujillo, Jonathan A., Luke, Jason J., Zha, Yuanyuan, Segal, Jeremy P., Ritterhouse, Lauren L., Spranger, Stefani, Matijevich, Karen, Gajewski, Thomas F. · 2019 · Journal for ImmunoTherapy of Cancer
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
Type I interferon signaling, regulation and gene stimulation in chronic virus infection
Sabelo Lukhele, Giselle M. Boukhaled, David G. Brooks · 2019 · Seminars in Immunology
Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction
József Tı́már, Andrea Ladányi · 2022 · International Journal of Molecular Sciences
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Heng Lin, Ilona Kryczek, Shasha Li, Michael D. Green, Alicia Ali, Reema Hamasha, Shuang Wei, Linda Vatan, Wojciech Szeliga, Sara Grove et al. · 2021 · Cancer Cell
Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
Sceneay, Jaclyn, Goreczny, Gregory J., Wilson, Kristin, Morrow, Sara, DeCristo, Molly J., Ubellacker, Jessalyn M., Qin, Yuanbo, Laszewski, Tyler, Stover, Daniel G., Barrera, Victor et al. · 2019 · Cancer Discovery
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment
Ronan Thibaut, Pierre Bost, Idan Milo, Marine Cazaux, Fabrice Lemaı̂tre, Zacarias Garcia, Ido Amit, Béatrice Bréart, Clémence Cornuot, Benno Schwikowski et al. · 2020 · Nature Cancer
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Jessica M. Moskovitz, Jennifer D. Moy, Robert Louis Ferris · 2018 · Current Oncology Reports
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han, Jing Nie · 2017 · Oncotarget
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
Roni Shouval, Ana Alarcon Tomas, Joshua Alexander Fein, Jessica R. Flynn, Ettai Markovits, Shimrit Mayer, Aishat Olaide Afuye, Anna Alperovich, Theodora Anagnostou, Michal Judith Besser et al. · 2021 · Journal of Clinical Oncology
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, Yilun Sun, Peng Liao, Shasha Li, Shuang Wei, Sara Grove, Linda Vatan, Reagan Nelson et al. · 2023 · Cancer Cell
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Shihong Zhang, Karan Kohli, Graeme Black, Yao Lu, Sydney M. Spadinger, Qianchuan He, Venu Gopal Pillarisetty, Lee D. Cranmer, Brian Andrew Van Tine, Cassian Yee et al. · 2019 · Cancer Immunology Research
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Shreyas Ramchandra Gaikwad, Manas Yogendra Agrawal, Itishree Kaushik, Sharavan Ramachandran, Sanjay Srivastava · 2022 · Seminars in Cancer Biology
Emerging Functions of Human IFIT Proteins in Cancer
Vijaya Kumar Pidugu, Hima Bindu Pidugu, Meei‐Maan Wu, Chung‐Ji Liu, Te-Chang Lee · 2019 · Frontiers in Molecular Biosciences
NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells
Samantha Xing, Lucas Ferrari de Andrade · 2020 · Clinical & Translational Immunology
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Mbofung, Rina M., McKenzie, Jodi A., Malu, Shruti, Zhang, Min, Peng, Weiyi, Liu, Chengwen, Kuiatse, Isere, Tieu, Trang, Williams, Leila, Devi, Seram et al. · 2017 · Nature Communications
Cancer Immunotherapy: Beyond Checkpoint Blockade
Michael Lawrence Dougan, Glenn Dranoff, Stephanie K. Dougan · 2018 · Annual Review of Cancer Biology
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Mirjam E. Hoekstra, Laura Bornes, Feline E. Dijkgraaf, Daisy Philips, Iris N. Pardieck, Mireille Toebes, Daniela S. Thommen, Jacco van Rheenen, Ton N. Schumacher · 2020 · Nature Cancer
IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
Wan Du, Timothy L. Frankel, Michael Green, Weiping Zou · 2021 · Cellular and Molecular Immunology
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients
Richard P. Tobin, Kimberly Rae Jordan, Puja Kapoor, Eric Spongberg, Dana M. Davis, Victoria M. Vorwald, Kasey L. Couts, Dexiang Gao, Derek E. Smith, Jessica S.W. Borgers et al. · 2019 · Frontiers in Oncology
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien, Catalina Rozalén, Toni Celià-Terrassa · 2021 · Journal of Clinical Investigation
Self‐Blockade of PD‐L1 with Bacteria‐Derived Outer‐Membrane Vesicle for Enhanced Cancer Immunotherapy
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou · 2021 · Advanced Materials
Cancer Immunoediting in the Era of Immuno-oncology
Matthew M. Gubin, Matthew D. Vesely · 2022 · Clinical Cancer Research
A vaccine targeting resistant tumours by dual T cell plus NK cell attack
Soumya Badrinath, Maxence O. Dellacherie, Aileen W. Li, Shiwei Zheng, Xixi Zhang, Miguel C. Sobral, Jason W. Pyrdol, Kathryn L. Smith, Yuheng Lu, Sabrina Haag et al. · 2022 · Nature
Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, Christopher Moore, Sareena Rana, Miriam Llorian, Philip East, Rachel Ambler, Panayiotis Anastasiou, Pablo Romero-Clavijo et al. · 2022 · Science Advances
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Andrew J. Freeman, Stephin J. Vervoort, Kelly M. Ramsbottom, Madison J. Kelly, Jessica Michie, Lizzy Pijpers, Ricky W. Johnstone, Conor J. Kearney, Jane Oliaro · 2019 · Cell Reports
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
Alice Newey, Beatrice L. Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews et al. · 2019 · Journal for ImmunoTherapy of Cancer
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Pai, Chien-Chun Steven, Huang, John T., Lu, Xiaoqing, Simons, Donald M., Park, Chanhyuk, Chang, Anthony, Tamaki, Whitney, Liu, Eric, Roybal, Kole T., Seagal, Jane et al. · 2019 · Immunity
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos · 2019 · Drug Resistance Updates
The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
Min Wang, Xiaoyang Zhai, Ji Li, Jingyuan Guan, Shuhui Xu, Yuying Li, Hui Zhu · 2021 · Frontiers in Immunology
Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas
Anushka Dongre, Mohammad Rashidian, Elinor Ng Eaton, Ferenc Reinhardt, Prathapan Thiru, Maria Zagorulya, Sunita Nepal, Tuba Banaz, Anna Martner, Stefani Spranger et al. · 2020 · Cancer Discovery
Type I and II Interferons in the Anti-Tumor Immune Response
Sarah Elizabeth Fenton, Diana Saleiro, Leonidas C. Platanias · 2021 · Cancers
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation
Wan Du, Fang Hua, Xiong Li, Jian Zhang, Shasha Li, Weichao Wang, Jiajia Zhou, Weimin Wang, Peng Liao, Yijian Yan et al. · 2021 · Cancer Discovery
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Jiashu Han, Mengwei Wu, Ziwen Liu · 2023 · Frontiers in Immunology